Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
- Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
- 06/27/2024
|
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
- 06/26/2024
|
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
- HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
- 06/03/2024
|
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
- 05/28/2024
|
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
- Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
- 05/22/2024
|
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva®.
- 05/21/2024
|
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/09/2024
|
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
- Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
- 05/08/2024
|
Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managing Director Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Neha Manpuria - Bank of America Merrill Lynch Kunal Dhamesha - Macquarie Capital Securities Saion Mukherjee - Nomura Securities Tarang Agrawal - Old Bridge Capital Tushar Manudhane - Motilal Oswal Financial Services Nitesh Dutt - Burman Capital Ankush Mahajan - Axis Securities Surya Patra - PhillipCapital India Private Limited. Madhav Marda - FIL Research Bino Pathiparampil - Elara Capital Operator Ladies and gentlemen, good day, and welcome to the Q4 and Full-Year FY2024 Earnings Conference Call of Dr. Reddy's Laboratories Limited.
- 05/07/2024
|
Dr. Reddy's Q4 & Full Year FY24 Financial Results
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
- 05/07/2024
|
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Capsules--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- 05/03/2024
|
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
- 04/18/2024
|
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 03/20/2024
|
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Avastin--Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
- 03/19/2024
|
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 02/28/2024
|
Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/23/2024
|
Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/22/2024
|
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 02/05/2024
|
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
- Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
- 02/01/2024
|
Dr. Reddy's Q3 & 9M FY24 Financial Results
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
- 01/31/2024
|
Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
- Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript
- 01/30/2024
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
- 01/25/2024
|
Here's Why Doctor Reddy's (RDY) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 01/08/2024
|
How to Identify Stock Market Winners Early in 2024
- With every year comes a different market theme.
- 01/03/2024
|
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.
- 01/03/2024
|
Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
- HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DJSIWorld--Dr. Reddy's has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agenda.
- 12/14/2023
|
Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/08/2023
|
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
- Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.
- 12/07/2023
|
India's Dr. Reddy's R&D centre being inspected by US FDA
- India's Dr Reddy's on Tuesday said that its research and development centre in Hyderabad is being inspected by the U.S. Food and Drug Administration.
- 12/05/2023
|
2 overlooked stocks that crushed earnings but traded lower
- As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings season has its share of misfits and heroes.
- 11/20/2023
|
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 11/02/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
- 10/30/2023
|
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
- Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
- 10/30/2023
|
Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript
- Dr Reddy's Laboratories Ltd (NYSE:RDY ) Q2 2024 Earnings Conference Call October 27, 2023 10:00 AM ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Mikaela Franceschina - Barclays Bank Kunal Dhamesha - Macquarie Research Neha Manpuria – Bank of America Merrill Lynch Gagan Thareja - ASK Investment Managers Aman Vij - Astute Investment Management Damayanti Kerai - HSBC Surya Patra - PhillipCapital Saion Mukherjee - Nomura Securities Tushar Manudhane - Motilal Oswal Financial Services Operator Ladies and gentlemen, good day, and welcome to the Dr. Reddy's Q2 FY '24 Earnings Conference Call. [Operator Instructions].
- 10/27/2023
|
All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy
- Doctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 10/26/2023
|
5 Top-Ranked Stocks With Compelling Relative Price Strength
- MRO. RDY, AEO, BTU and SKX are five stocks with explosive relative price strength.
- 10/20/2023
|
3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)
- Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.
- 10/04/2023
|
Protect Your Portfolio From Volatility With 3 Low-Beta Picks
- At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.
- 09/29/2023
|
Want to Shrug Off Volatility? Buy 3 Medical Growth Stocks
- We pick three medical stocks - MOH, RDY and NRBO - that have gained more than 5% in the past three months amid market volatility.
- 09/28/2023
|
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 09/26/2023
|
Navigate Volatility With These 3 Low-Beta Stocks
- Low-beta stocks can provide many beneficial advantages for investors, including a more defensive nature and overall portfolio balance.
- 09/19/2023
|
Discount Alert: 3 Top Ranked Stocks Trading Below Historical Valuations
- In the ever-evolving financial markets, savvy investors are always on the lookout for golden opportunities that offer great value. While the headlines often spotlight stocks that are soaring to new heights, some of the best investment prospects lie in stocks trading below their historical valuations.
- 09/19/2023
|
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now
- Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.
- 09/18/2023
|
5 Dividend Growth Stocks for Steady Returns in Uncertain Times
- Caterpillar (CAT), KB Home (KBH), Walmart (WMT), Dr. Reddy's (RDY) and FedEx (FDX) could be solid choices amid the current market volatility.
- 09/12/2023
|
These 3 Low-Beta Stocks Sport High Growth
- Low-beta stocks can provide many beneficial advantages for investors, including a more defensive nature and overall portfolio balance. And for those seeking this approach, these three stocks are great considerations.
- 09/08/2023
|
Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice
- Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.
- 08/31/2023
|
Enrich Your Portfolio With These 4 Top-Ranked Liquid Stocks
- Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and NVIDIA (NVDA), which investors can add to their portfolio for solid gains.
- 08/30/2023
|
5 Dividend Growth Stocks to Buy in a Weak Market
- Caterpillar (CAT), Applied Materials (AMAT), Toll Brothers (TOL), Walmart (WMT) and Dr. Reddy's (RDY) could be solid choices for investors amid market weakness.
- 08/28/2023
|
Buy These 4 Low-Beta Stocks to Sail Through the Choppy Market
- It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), J&J Snack (JJSF) and Granite Ridge (GRNT) are poised to gain.
- 08/25/2023
|
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
- Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
- 08/18/2023
|
5 Growth Opportunities Thriving on Relative Price Strength
- HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.
- 08/18/2023
|
Add These 4 Top-Performing Liquid Stocks for Strong Returns
- Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.
- 08/18/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
- 08/11/2023
|
Buy These 4 Low-Beta Stocks to Counter the Choppy Market
- It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.
- 08/09/2023
|
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
- Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
- 07/28/2023
|
Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
- Dr. Reddy's Laboratories Ltd. (RDY) remains an attractive investment due to its strong Q4 and FY'23 numbers, exposure to the Indian generics market, and consistent new product launches. RDY is well-positioned in the high-growth generics market, along with other favorable business economics. Findings suggest RDY stock could be a buy with a target price of $60/share.
- 06/07/2023
|
Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study
- Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.
- 06/06/2023
|
The 3 Most Undervalued Value Stocks to Buy in June 2023
- With the market facing myriad pressure points – predominantly stubbornly high inflation along with general anxieties about an incoming recession – the bright side is that investors have options regarding the best undervalued value stocks for June. Still, you don't want to just chase deflated entities just because they're down.
- 06/04/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 05/23/2023
|
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/11/2023
|
Dr Reddy's Laboratories Ltd (RDY) Q4 2023 Earnings Call Transcript
- Dr Reddy's Laboratories Ltd (NYSE:RDY ) Q4 2023 Earnings Conference Call May 10, 2023 10:00 AM ET Company Participants Richa Periwal - IR Gunupati Prasad - Co-Chairman Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Balaji Prasad - Barclays Bank Surya Patra - PhillipCapital Damayanti Kerai - HSBC Cyndrella Carvalho - JM Financial Ankush Mahajan - Axis Securities Nitin Agarwal - DAM Capital Advisors Madhav Marda - FI Industries Tushar Manudhane - Motilal Oswal Financial Services Kunal Dhamesha - Macquarie Research Neha Manpuria - Bank of America Merrill Lynch Ashish Chopra - IIFL Asset Management Prakash Agarwal - Axis Capital Limited Operator Ladies and gentlemen, good day, and welcome to the Dr. Reddy's Q4 FY '23 Earnings Conference Call. [Operator Instructions].
- 05/11/2023
|
Dr. Reddy's: A Profitable, Predictable Margin Expander
- The Profitable Predictable Margin Expanders screener on GuruFocus has been a helpful one for me when searching for quality stocks that show solid growth. It does what the name suggests - it sorts through the thousands of stocks in the GuruFocus database and selects those that are currently profitable, have a business predictability ranking of at least 3 out of 5 stars and have expanding operating margins.
- 05/08/2023
|
U.S. Economy Suffering From Dichotomy: 5 Safe Stocks
- We have selected five defensive stocks with strong momentum. These are: CAG, COTY, NEE, NJR, RDY.
- 04/13/2023
|
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
- COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
- 03/21/2023
|
5 Top-Ranked Dividend Stocks to Counter Market Volatility
- Dr. Reddys (RDY), Darden Restaurants (DRI), Interpublic Group (IPG), Microchip Technology (MCHP) and Valero Energy (VLO) could be compelling picks amid market volatility.
- 03/21/2023
|
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 03/06/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 03/03/2023
|
Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
- Growth in key emerging markets, including India and Russian footprint. Positive Q3 FY23 results with top–bottom line growth. Solid FCF conversion and returns on capital.
- 02/16/2023
|
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 02/08/2023
|
The 3 Most Undervalued Stocks in India for Your February Buy List
- The Indian markets have been in focus with the recent Hindenburg Research report on the Adani Group. The report alleges that the group has pulled off the “largest con in corporate history.
- 01/31/2023
|
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
- Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
- 01/27/2023
|
Dr. Reddy's Laboratories Limited (RDY) Q3 2023 Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2023 Earnings Conference Call January 25, 2023 8:30 AM ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Amit Agarwal - Head, IR & Director, Finance Conference Call Participants Kunal Dhamesha - Macquarie Group Damayanti Kerai - HSBC Surya Patra - Philip Capital Prakash Agarwal - Axis Capital Sameer Baisiwala - Morgan Stanley Prashant Nair - Ambit Capital Saion Mukherjee - Nomura Rahul Singh - IIFL Securities Shyam Srinivasan - Goldman Sachs Operator Ladies and gentlemen, good day, and welcome to Dr. Reddy's Laboratories Limited Q3 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
- 01/25/2023
|
New Strong Buy Stocks for January 10th
- STNE, JD, VSH, MOMO and RDY have been added to the Zacks Rank #1 (Strong Buy) List on January 10 , 2023.
- 01/10/2023
|
5 Best Emerging Markets Stocks to Buy for 2023
- Here are five emerging market stocks, JD, SGML, RDY, MMYT and CPNG that are expected to gain enormously in 2023, capitalizing on their growth prospects.
- 12/21/2022
|
3 Generic Drug Stocks to Watch Amid Inflation Pressures
- The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
- 12/07/2022
|
New Strong Buy Stocks for November 17th
- PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.
- 11/17/2022
|
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
- TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
- 11/04/2022
|
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
- Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
- 10/31/2022
|
Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2023 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Tarang Agarwal - Old Bridge Capital Prakash Agarwal - Axis Capital Kunal Dhamesha - Macquarie Capital Damayanti Kerai - HSBC Surya Patra - Philip Capital Operator Ladies and gentlemen, good day, and welcome to Q2 FY '23 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.
- 10/28/2022
|
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 10/07/2022
|
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
- The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
- 09/09/2022
|
Plaintiff in first Zantac lawsuit set for trial drops case
- The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
- 08/17/2022
|
Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth
- Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treatment market.
- 07/31/2022
|
Dr. Reddy's Laboratories Limited's (RDY) CEO Erez Israeli on Q1 2023 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2023 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Saion Mukherjee - Nomura Anubhav Aggarwal - Credit Suisse Damayanti Kerai - HSBC Prakash Agarwal - Axis Capital Neha Manpuria - Bank of America Sameer Baisiwala - Morgan Stanley Surya Patra - Philip Capital Tarang Agarwal - Old Bridge Capital Kunal Dhamesha - Macquarie Darshan Jhaveri - Crown Capital Madhav Marda - FIS International Operator Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in listen-only mode.
- 07/31/2022
|
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
- Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
- 07/29/2022
|
New Strong Sell Stocks for May 20th
- Teaser: CBAN, CHUY, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2022.
- 05/20/2022
|
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q4 2022 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Gunupati Prasad - Co-Chairman & Managing Director Erez Israeli - Chief Executive Officer Parag Agarwal - Chief Financial Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Surya Patra - Philip Capital Nikhil Mathur - HDFC Mutual Fund Prakash Agarwal - Axis Capital Sameer Baisiwala - Morgan Stanley Vishal Manchanda - Nirmal Bang Nitin Agarwal - DAM Capital Vinod B - InCred Capital Operator Ladies and gentlemen, good day and welcome to the Q4 FY '22 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] Please note that this conference is being recorded.
- 05/19/2022
|
New Strong Sell Stocks for May 18th
- ALX, CBAN, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2022.
- 05/18/2022
|
New Strong Sell Stocks for May 12th
- CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.
- 05/12/2022
|
These Pot Stocks Went Wild This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we kick off 2022.
- 02/04/2022
|
NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH
- Pharmaceutical company Dr. Reddy's Laboratories Ltd. RDY has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from Germany.
- 02/04/2022
|
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
- Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
- 01/31/2022
|
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2022 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2022 Results - Earnings Call Transcript
- 01/28/2022
|
Why Stocks Were Down Today: What To Know Now As Markets Sell-Off
- Stock market wrap up for January 27, 2022 The post Why Stocks Were Down Today: What To Know Now As Markets Sell-Off appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/27/2022
|
Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters
- India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's would launch the molnupiravir generic at ₹35 ($0.4693) per capsule.
- 01/04/2022
|
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
- The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
- 12/29/2021
|
New Strong Sell Stocks for November 22nd
- RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.
- 11/22/2021
|
Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters
- Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can be used to treat patients once they contract coronavirus infection and are expected to be a substantial market.
- 11/16/2021
|
New Strong Sell Stocks for November 4th
- ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.
- 11/04/2021
|
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules, from
- 10/19/2021
|
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA). The BiCNU® brand and generic market had U.S. sales of approximately $19.4 million MAT for the
- 10/15/2021
|
Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”), announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. (“Citius”) pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets. Under the terms of agreement, Dr. Reddy's will receive
- 09/04/2021
|
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
- HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. “Our launch of Reddy
- 09/02/2021
|
Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax® (chlordiazepoxide hydrochloride and clidinium bromide) approved by the U.S. Food and Drug Administration (USFDA). The Librax® bran
- 08/31/2021
|
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
- The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
- 08/17/2021
|
Dr. Reddy's Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). “The re-launch of Dr. Reddy's Naproxen Sodium Tablets, 220 mg (OTC), is an impo
- 08/03/2021
|
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q1 2021 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q1 2021 Results - Earnings Call Transcript
- 07/27/2021
|
2 Top Global Value Stocks to Buy Now
- Don't want to pay too steep a price for high-quality stocks? Look abroad.
- 07/08/2021
|
Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced that its Annual Report on Form 20-F containing its consolidated financial statements for the fiscal year ended March 31, 2021 and prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board was filed with the U
- 06/30/2021
|
Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market
- HYDERABAD, India and Princeton, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Icosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with s
- 06/22/2021
|
Global Response Aid Reports Midyear Sales Results for COVID Drug
- DUBAI, UAE, June 3, 2021 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19. "Over the course of a year, GRA has signed a global licensing agreement for Avigan® with its developer, FujiFilm Toyama, filed a drug dossier with various regulators, and recently initiated a global Phase 3 clinical trial in an outpatient setting," said GRA CEO Mitch Wilson.
- 06/03/2021
|
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
- Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
- 05/17/2021
|
Dr.Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q4 2021 Results - Earnings Call Transcript
- Dr.Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q4 2021 Results - Earnings Call Transcript
- 05/14/2021
|
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring this important product to market at this t
- 05/12/2021
|
3 Global Value Stocks to Buy Now
- Tired of expensive stocks being just of reach? Look abroad for some great buying opportunities.
- 05/07/2021
|
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA). The Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve mont
- 04/29/2021
|
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 04/14/2021
|
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act. In September 2020, Dr. Reddy's had partnered with the Russian Direct Investment Fund (R
- 04/13/2021
|
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to lau
- 04/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for...
- 03/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....
- 03/03/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for...
- 02/22/2021
|
Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA). The Prevacid® brand and generic
- 02/22/2021
|
Dr. Reddy's Starts EUA Process For Russia's Sputnik V COVID-19 Vaccine In India
- Dr. Reddy's Laboratories Ltd (NYSE: RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization (EUA) of the human adenoviral vector-based platform COVID-19 vaccine candidate, Sputnik V. As part of the review process, Dr. Reddy's will present the Phase 2 study's safety profile and interim data of the phase 3 study, which is expected to complete by February 21.
- 02/19/2021
|
Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced that it has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V. As part of the review process, Dr. Reddy's will present the safety profile of the pha
- 02/19/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....
- 02/19/2021
|
Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA). The Prolixin brand and generic had U.S. sales of approximately $134 mi
- 02/18/2021
|
Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market
- HYDERABAD, India and PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelv
- 02/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for...
- 02/15/2021
|
Allstate, Cirrus Logic, EA, Zillow and More Tuesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were pushing much higher on Tuesday.
- 02/02/2021
|
Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril® (vigabatrin) Tablets, USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased that this product has been designated as a Competitive Generic Therapy (CGT)
- 02/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....
- 02/02/2021
|
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
- Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
- 02/01/2021
|
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2021 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2021 Results - Earnings Call Transcript
- 01/29/2021
|
Dr. Reddy's Q3 & 9M FY21 Financial Results
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the nine months ended December 31, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). Q3 Performance Summary 9M Performance Summary Rs. 4,930 Cr Rs. 14,244 Cr Revenue Revenue [Up: 12% YoY; 1%
- 01/29/2021
|
Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19
- Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.
- 01/28/2021
|
Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies
- KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and Global Response Aid FZCO (GRA) today announced results from an Avigan study on...
- 01/27/2021
|
Dr. Reddy's and GRA announces Avigan Pivotal Studies Update
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting. The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical pro
- 01/27/2021
|
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
- Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
- 01/18/2021
|
Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and Safety Monitoring Board (DSMB) revi
- 01/15/2021
|
Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months
- 01/11/2021
|
Dr. Reddy's to Release Q3 FY 21 Results on January 29th, 2021
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting. Summary of Events Event Date and Time Medium Release of financial results January 29th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email Press meet presentation Will be available on the Company's website Compan
- 01/08/2021
|
4 Emerging Market Stocks to Tap 2021 Economic Rebound
- Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.
- 12/28/2020
|
Bernstein Favors India's Cipla, Dr. Reddy's, Sun Pharma, Lupin
- Dec.16 -- Nithya Balasubramanian, health-care analyst at Bernstein, discusses the prospects for Covid-19 vaccine approvals in India, and the outlook for the country's pharmaceutical industry. She speaks with Rishaad Salamat and Juliette Saly during the "India Focus" segment on "Bloomberg Markets: Asia.
- 12/17/2020
|
Secondary Listing of Dr. Reddy's ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy's”) today announced the secondary listing of its American Depository Receipts (ADRs) on NSE IFSC Limited under the symbol 'DRREDDY' on December 9, 2020. NSE IFSC Limited is a recognized international stock exchange established in the International Financial Services Centre (“IFSC”), GIFT City Gujarat, India. IFSC is one of the permissible jurisdictio
- 12/09/2020
|
Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India. This will be a multicenter and randomized controlled study, which will include safety and immunogenicity study. The clinical trials are being conducted by
- 12/01/2020
|
Dr. Reddy's Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor
- HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced a preclinical data presentation for E7777 (denileukin diftitox), its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, being held virtually. Dr. Anil Namboodiripad, Senior Vice President and Head of Dr. Reddy's P
- 11/09/2020
|
Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19
- HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with Dr. Reddy's Laboratories Ltd. (BSE:500124, NSE:DRREDDY, NYSE:RDY, “Dr. Reddy's”) and Global Response Aid (“GRA”). This agreement follows on and is harmonized with the previously announced global licensing transaction (
- 10/30/2020
|
Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India. The partnership will allow Dr. Reddy's to identify and use some of BIRAC's clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM),
- 10/29/2020
|
Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript
- Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript
- 10/28/2020
|
Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designate) on November 2, 2020. The Board of Directors at their meeting held today, has approved his appointment as a Chief Financial Officer (KMP*) of the Company effective December 1, 2020. In a career spanning over 33 years, Parag has held several leadership positions, contributing significantly to t
- 10/28/2020
|
Dr. Reddy's Q2 & H1 FY21 Financial Results
- HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). Q2 Performance Summary H1 Performance Summary Rs. 4,897 Cr Rs. 9,314 Cr Revenue Revenue [Up: 11% QoQ; 2% YoY] [Up: 8% YoY] 53
- 10/28/2020
|
